DY131, also known as GSK-9089, is a novel selective agonist at estrogen-related receptors ERRβ and ERRγ. DY131 could potentiate the ERRgamma-induced growth inhibition in LNCaP-ERRgamma and DU145-ERRgamma cells in a dose-dependent manner. ERRgamma may perform an antiproliferative or tumor-suppressing function in prostate cancer cells. ERRgamma could be a novel therapeutic target for prostate cancer treatment.
Estrogen/progestogen Receptor Inhibitors Related Products:
Quinestrol; Lynestrenol; Mestranol; AZD9496; Mifepristone; GSK5182; Levonorgestrel; Medroxyprogesterone Acetate; Progesterone; Estriol; Estrone; Bazedoxifene Acetate; Endoxifen HCl; Altrenogest; Zearalenone; Etonogestrel; Dienogest; Gestodene; Allylestrenol